Indeed, it was recently reported that, for prostate cancer patients with docetaxel treatment, ABCG2 rs2231142 correlates with improved drug response, but also correlates with poorer outcomes possibly through increasing intratumoral folate levels and thereby enhancing tumor cell proliferation 47. This evidence concerns the gene ABCG2 and Familial prostate cancer.